
Doc.ai
Blockchain based AI that performs deep learning computations on quantified biology for predictive analytics and personal health insights.
Date | Investors | Amount | Round |
---|---|---|---|
- | investor investor investor investor | €0.0 | round |
investor | €0.0 | round | |
investor investor investor investor | €0.0 | round | |
N/A | €0.0 | round | |
N/A | €0.0 | round | |
N/A | Acquisition | ||
Total Funding | 000k |
Related Content
Doc.ai was established in 2016 by the husband-and-wife team, Walter and Sam De Brouwer. The company positioned itself at the intersection of artificial intelligence and healthcare, aiming to empower individuals by giving them greater control over their health data. Walter De Brouwer brought a background as a technology entrepreneur, having been involved with startups since the 1990s, while Sam De Brouwer had a history in community building and patient advocacy, notably as a co-founder of Scanadu, a medical tricorder company. Their combined experience in technology and healthcare advocacy shaped the company's mission.
The core of Doc.ai's business was a platform that utilized advanced artificial intelligence, including natural language processing and computer vision, to analyze various forms of health data. This allowed users to collect, manage, and understand their medical information from a single, secure point of access. The platform could process a wide range of data types, from lab results and genetic information to data from wearable devices. For enterprises, Doc.ai offered solutions for accelerating clinical trials and research by providing tools for patient monitoring and data collection. This B2B approach formed a significant part of its business model, generating revenue by licensing its AI-powered platform to pharmaceutical companies and research institutions.
One of the key services offered was the creation of a 'digital twin' for users, a personalized, dynamic representation of an individual's health profile. This feature provided users with predictive insights and personalized health recommendations. For its business clients, the platform offered a way to decentralize clinical trials, making participant recruitment and data gathering more efficient and cost-effective. In a significant milestone, Doc.ai was acquired by Sharecare, a digital health company, in January 2021. The acquisition aimed to integrate Doc.ai's AI capabilities into Sharecare's broader platform to enhance personalized health management for a larger user base. Following the acquisition, the Doc.ai brand and its specific offerings were absorbed into the Sharecare ecosystem.
Keywords: artificial intelligence, healthcare data, digital health, clinical trials, natural language processing, medical information, patient data, decentralized research, health insights, data analytics